OverviewSuggest Edit

Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary antibody drug conjugate, or ADC, platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. It engineers immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because the Company can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

TypePublic
Founded2005
HQCambridge, MA, US
Websitemersana.com
Employee Ratings4.9

Latest Updates

Employees (est.) (Jan 2019)86(+11%)
Revenue (FY, 2016)$25.2 M(+143%)
Share Price (Jun 2021)$14.9
Cybersecurity ratingCMore

Key People/Management at Mersana Therapeutics

David Mott

David Mott

Chairman
Lawrence Alleva

Lawrence Alleva

Director
Brian C. Deschuytner

Brian C. Deschuytner

Senior Vice President of Finance and Product Strategy
Kristen M. Hege

Kristen M. Hege

Director
Arvin Yang

Arvin Yang

Senior Vice President and Chief Medical Officer
Anna Protopapas

Anna Protopapas

President and Chief Executive Officer, Director
Show more

Mersana Therapeutics Office Locations

Mersana Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
840 Memorial Dr
Show all (1)

Mersana Therapeutics Financials and Metrics

Mersana Therapeutics Revenue

Mersana Therapeutics's revenue was reported to be $25.17 m in FY, 2016 which is a 143% increase from the previous period.
USD

Revenue (FY, 2016)

25.2m

Revenue growth (FY, 2015 - FY, 2016), %

143%

Net income (FY, 2016)

(13.7m)

Market capitalization (11-Jun-2021)

1.0b

Closing stock price (11-Jun-2021)

14.9

Cash (31-Dec-2016)

100.3m
Mersana Therapeutics's current market capitalization is $1 b.
USDFY, 2015FY, 2016

Revenue

10.4m25.2m

Revenue growth, %

143%

General and administrative expense

5.3m7.0m

R&D expense

21.4m32.0m
USDFY, 2015FY, 2016

Cash

11.5m100.3m

Accounts Receivable

640.0k1.1m

Current Assets

12.8m102.2m

PP&E

1.3m2.5m
USDFY, 2015FY, 2016

Net Income

(16.4m)(13.7m)

Depreciation and Amortization

297.0k655.0k

Accounts Payable

926.0k(325.0k)

Cash From Operating Activities

(9.6m)31.6m
USDFY, 2015

Financial Leverage

-0.3 x
Show all financial metrics

Mersana Therapeutics Operating Metrics

Apr, 2017

Patents (US)

7

Patents Pending (US)

10
Show all operating metrics

Mersana Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Mersana Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Mersana Therapeutics Online and Social Media Presence

Embed Graph

Mersana Therapeutics News and Updates

Mersana Therapeutics to Present at Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that An…

Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business Updates

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it…

Mersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer

CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the …

Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting

CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today presented precl…

Thinking about buying stock in Curiositystream, Mersana Therapeutics, Energous Corp, Sogou, or SelectQuote?

NEW YORK, April 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CURI, MRSN, WATT, SOGO, and SLQT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path

Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET
Show more

Mersana Therapeutics Blogs

Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update Content Import Mon, 05/10/2021 - 16:01 Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update May 10, 2021 This release …

Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors

Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors Content Import Thu, 03/11/2021 - 08:00 Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors March 11, 2021 This release is a backfill from a News Wire …

Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference Content Import Wed, 11/04/2020 - 08:01 Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference November 4, 2020 This release is a bac…

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates Content Import Mon, 11/02/2020 - 08:01 Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates November…

Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting Content Import Wed, 10/14/2020 - 17:05 Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-…

Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress

-  Company to Host Conference Call and Webcast Featuring Study Investigator, Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET - CAMBRIDGE, Mass. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering
Show more

Mersana Therapeutics Frequently Asked Questions

  • When was Mersana Therapeutics founded?

    Mersana Therapeutics was founded in 2005.

  • Who are Mersana Therapeutics key executives?

    Mersana Therapeutics's key executives are David Mott, Lawrence Alleva and Brian C. Deschuytner.

  • How many employees does Mersana Therapeutics have?

    Mersana Therapeutics has 86 employees.

  • What is Mersana Therapeutics revenue?

    Latest Mersana Therapeutics annual revenue is $25.2 m.

  • What is Mersana Therapeutics revenue per employee?

    Latest Mersana Therapeutics revenue per employee is $292.7 k.

  • Who are Mersana Therapeutics competitors?

    Competitors of Mersana Therapeutics include Araris Biotech, Intas Pharmaceuticals and Akumentis Healthcare.

  • Where is Mersana Therapeutics headquarters?

    Mersana Therapeutics headquarters is located at 840 Memorial Dr, Cambridge.

  • Where are Mersana Therapeutics offices?

    Mersana Therapeutics has an office in Cambridge.

  • How many offices does Mersana Therapeutics have?

    Mersana Therapeutics has 1 office.